213 related articles for article (PubMed ID: 23870042)
21. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
MacDiarmid SA
BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
[TBL] [Abstract][Full Text] [Related]
22. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
23. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study.
Park SJ; Pai KS; Kim JM; Park K; Kim KS; Song SH; Park S; Kim SO; Ryu DS; Baek M; Lee SD; Lee JW; Im YJ; Han SW; Chung JM; Cho MH; Ha TS; Cho WY; Suh HJ;
J Korean Med Sci; 2014 Nov; 29(11):1550-4. PubMed ID: 25408588
[TBL] [Abstract][Full Text] [Related]
26. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.
Nabi G; Cody JD; Ellis G; Herbison P; Hay-Smith J
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD003781. PubMed ID: 17054185
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
[TBL] [Abstract][Full Text] [Related]
28. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
29. [Anticholinergic drugs in overactive bladder].
Muhlstein J; Deval B
Gynecol Obstet Fertil; 2008 Jan; 36(1):90-6. PubMed ID: 18178506
[TBL] [Abstract][Full Text] [Related]
30. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly.
Scheife R; Takeda M
Clin Ther; 2005 Feb; 27(2):144-53. PubMed ID: 15811477
[TBL] [Abstract][Full Text] [Related]
31. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence.
Kalder M; Pantazis K; Dinas K; Albert US; Heilmaier C; Kostev K
Obstet Gynecol; 2014 Oct; 124(4):794-800. PubMed ID: 25198276
[TBL] [Abstract][Full Text] [Related]
32. Overactive bladder medication adherence when medication is free to patients.
Sears CL; Lewis C; Noel K; Albright TS; Fischer JR
J Urol; 2010 Mar; 183(3):1077-81. PubMed ID: 20092838
[TBL] [Abstract][Full Text] [Related]
33. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
34. [New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder].
García-Baquero R; Madurga B; García MV; Fernández MA; Rosety JM; Álvarez-Ossorio JL
Actas Urol Esp; 2013 Feb; 37(2):83-91. PubMed ID: 23374672
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
Grigoleit U; Mürtz G; Laschke S; Schuldt M; Goepel M; Kramer G; Stöhrer M
Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
[TBL] [Abstract][Full Text] [Related]
36. Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database.
Malcher MF; Droupy S; Berr C; Ziad A; Huguet H; Faillie JL; Serrand C; Mura T
J Urol; 2022 Oct; 208(4):863-871. PubMed ID: 35686842
[TBL] [Abstract][Full Text] [Related]
37. [Anticholinergics do not affect the sexual function in women diagnosed with multiple sclerosis].
Di Marco J; De Broglie C; Manceau P; Weglinski L; Le Breton F; Verrollet D; Amarenco G
Prog Urol; 2016 Mar; 26(4):226-9. PubMed ID: 26826771
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported reasons for discontinuing overactive bladder medication.
Benner JS; Nichol MB; Rovner ES; Jumadilova Z; Alvir J; Hussein M; Fanning K; Trocio JN; Brubaker L
BJU Int; 2010 May; 105(9):1276-82. PubMed ID: 19912188
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
40. Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy?
Tran AM; Reis R; Iyer S; Botros C; Goldberg RP; Sand PK; Botros SM
Female Pelvic Med Reconstr Surg; 2018; 24(3):237-240. PubMed ID: 28957959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
